Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

about

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion.

P2860

Q37669520-B66FBC99-36D6-4C9D-B028-62CF961B9ACA

P2860

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

Item

http://www.wikidata.org/entity/Q51471678

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Comparison between ranibizumab ...... entral retinal vein occlusion.

@en

Comparison between ranibizumab ...... entral retinal vein occlusion.

@nl

type

Item

label

Comparison between ranibizumab ...... entral retinal vein occlusion.

@en

Comparison between ranibizumab ...... entral retinal vein occlusion.

@nl

prefLabel

Comparison between ranibizumab ...... entral retinal vein occlusion.

@en

Comparison between ranibizumab ...... entral retinal vein occlusion.

@nl

P1476

Comparison between ranibizumab ...... entral retinal vein occlusion.

@en

P2093

Masahito Ohji

http://www.w3.org/2001/XMLSchema#string

Masato Fujikawa

http://www.w3.org/2001/XMLSchema#string

Tomoko Sawada

http://www.w3.org/2001/XMLSchema#string

Yoshitsugu Saishin

http://www.w3.org/2001/XMLSchema#string

Yuka Ito

http://www.w3.org/2001/XMLSchema#string

P2860

Retinal vein occlusion: beyond the acute event.

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Treatments for macular oedema following central retinal vein occlusion: systematic review.

Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.

Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.

Visual acuity and foveal thickness after vitrectomy for macular edema.

Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.

P2888

s10384-016-0476-7

P304

67-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10384-016-0476-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27660163

http://www.w3.org/2001/XMLSchema#string

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

about

P2860

P2860

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698